Brown Brothers Harriman & Co’s Vaxcyte PCVX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.21M	Hold	38,033	–	–	0.01%	342
2026 Q1	$2.21M	Hold	38,033	–	–	0.01%	289
2025 Q4	$1.75M	Hold	38,033	–	–	0.01%	298
2025 Q3	$1.37M	Hold	38,033	–	–	0.01%	302
2025 Q2	$1.24M	Hold	38,033	–	–	0.01%	303
2025 Q1	$1.44M	Hold	38,033	–	–	0.01%	257
2024 Q4	$3.11M	Hold	38,033	–	–	0.02%	190
2024 Q3	$4.35M	Hold	38,033	–	–	0.03%	165
2024 Q2	$2.87M	Hold	38,033	–	–	0.02%	177
2024 Q1	$2.6M	Hold	38,033	–	–	0.02%	179
2023 Q4	$2.39M	Hold	38,033	–	–	0.02%	184
2023 Q3	$1.94M	Hold	38,033	–	–	0.02%	191
2023 Q2	$1.9M	Hold	38,033	–	–	0.02%	183
2023 Q1	$1.43M	Hold	38,033	–	–	0.01%	212
2022 Q4	$1.82M	Hold	38,033	–	–	0.02%	165
2022 Q3	$913K	Hold	38,033	–	–	0.01%	228
2022 Q2	$828K	Hold	38,033	–	–	0.01%	245
2022 Q1	$918K	Hold	38,033	–	–	0.01%	260
2021 Q4	$905K	Hold	38,033	–	–	0.01%	254
2021 Q3	$965K	Hold	38,033	–	–	0.01%	229
2021 Q2	$856K	Hold	38,033	–	–	0.01%	252
2021 Q1	$751K	Buy	+38,033	New	+$957K	﹤0.01%	255

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Brown Brothers Harriman & Co's PCVX Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its Vaxcyte (PCVX) position steady in Q2 2026 at 38,033 shares worth $2.21M. The position accounts for 0.01% of the portfolio, ranked #342.

Brown Brothers Harriman & Co first reported a position in PCVX in Q1 2021 and has held it in 22 quarters since. The position peaked at $4.35M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Brown Brothers Harriman & Co held 38,033 shares of Vaxcyte worth $2.21M as of Q2 2026.
Brown Brothers Harriman & Co left its Vaxcyte share count unchanged in Q2 2026.
Vaxcyte made up 0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #342 holding.
Brown Brothers Harriman & Co first reported a position in Vaxcyte in Q1 2021 and has held it in 22 quarters since.
Brown Brothers Harriman & Co's Vaxcyte position peaked at $4.35M in Q3 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.